Recombinant CA9 (Girentuximab Biosimilar) anticorps
Research Grade
Reactivité: Humain
ELISA, WB
Hôte: Human, Souris
Chimeric
unconjugated
Recombinant Antibody
-
- Antigène Tous les produits CA9 (Girentuximab Biosimilar)
- CA9 (Girentuximab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
- Human, Souris
- Expression System
- Mammalian cells
-
Clonalité
- Chimeric
-
Conjugué
- Cet anticorp CA9 (Girentuximab Biosimilar) est non-conjugé
- Application
- ELISA, Western Blotting (WB)
- Fonction
- Girentuximab Biosimilar - Anti-CA9 mAb - Research Grade
- Attributs du produit
- Antibody Type: IgG1-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Pureté
- > 85%
- Classe de qualité
- Research Grade
- Isotype
- IgG1 kappa
-
anti-CA9 (Girentuximab Biosimilar) antibody
Research Grade Reactivité: Humain ELISA, FACS Hôte: Souris Chimeric unconjugated Recombinant Antibody
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS buffer PH7.5
- Stock
- -80 °C
- Stockage commentaire
- store at -80°C
-
- Antigène
- CA9 (Girentuximab Biosimilar)
- Abstract
- CA9 (Girentuximab Biosimilar) Produits
- Classe de substances
- Biosimilar
- Sujet
- Recombinant chimeric antibody binding to human CA9. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.
- Numéro CAS
- 916138-87-9
-
Vous êtes ici:
